NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine hydrochloride is a sympathomimetic amine that acts as a direct and indirect alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.
| Metabolism | Naproxen: primarily metabolized by hepatic CYP2C9 to inactive metabolites. Pseudoephedrine: partially metabolized by hepatic N-demethylation (CYP2B6, CYP2C19); predominantly excreted unchanged in urine. |
| Excretion | Naproxen: ~95% renal (primarily as unchanged drug and conjugates), <5% biliary. Pseudoephedrine: 70-90% renal (unchanged), remainder hepatic metabolism. |
| Half-life | Naproxen: 12-17 hours (terminal), allowing twice-daily dosing; prolonged in elderly or renal impairment. Pseudoephedrine: 4-6 hours (pH-dependent; shorter with acidic urine, prolonged with alkaline urine). |
| Protein binding | Naproxen: >99% bound to albumin. Pseudoephedrine: negligible (<20%) binding to plasma proteins. |
| Volume of Distribution | Naproxen: 0.16 L/kg. Pseudoephedrine: 2.5-4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: Naproxen 95% (fasted); Pseudoephedrine 100% (immediate-release). |
| Onset of Action | Oral: Naproxen 1-2 hours (analgesic); Pseudoephedrine 30-60 minutes (decongestant). |
| Duration of Action | Naproxen: 7-12 hours (analgesic/anti-inflammatory). Pseudoephedrine: 4-6 hours (immediate-release); extended-release formulations up to 12 hours. |
| Molecular Weight | Naproxen sodium: 252.24 Da; Pseudoephedrine hydrochloride: 201.70 Da |
One tablet (naproxen sodium 220 mg/pseudoephedrine HCl 120 mg) orally every 12 hours; maximum 2 tablets in 24 hours. For extended-release formulations: one tablet (naproxen sodium 440 mg/pseudoephedrine HCl 240 mg) orally every 12 hours; maximum 2 tablets in 24 hours.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in GFR <30 mL/min. For GFR 30-59 mL/min: use with caution, reduce naproxen dose by 50% or avoid; consider shortest duration. For GFR ≥60 mL/min: no adjustment necessary. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce naproxen dose by 50%; avoid use if possible. Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended for children under 12 years. For children ≥12 years: same as adult dosing (one tablet every 12 hours). Weight-based naproxen alone: 5-7 mg/kg/dose every 8-12 hours, max 15 mg/kg/day; pseudoephedrine: 4 mg/kg/day divided every 6 hours, max 240 mg/day. Use fixed-dose combination only if both components are needed. |
| Geriatric use | Avoid use in patients ≥65 years due to increased risk of gastrointestinal bleeding, renal impairment, and cardiovascular events. If necessary, use lowest effective dose for shortest duration; monitor renal function and blood pressure closely. |
| 1st trimester | Avoid due to risk of NSAID-associated miscarriage and potential teratogenicity. Pseudophedrine may be associated with gastroschisis risk. |
| 2nd trimester | Use only if benefit outweighs risk. NSAIDs may cause oligohydramnios and premature closure of ductus arteriosus after 20 weeks. |
| 3rd trimester | Contraindicated. NSAIDs cause premature closure of ductus arteriosus and fetal renal dysfunction. Pseudoephedrine may cause uterine vasoconstriction. |
Clinical note
MAOIs can cause hypertensive crisis Can cause insomnia and tachycardia.
| Placental transfer | Both components cross the placenta. Naproxen is highly protein-bound and crosses to a moderate degree. Pseudoephedrine crosses readily, with fetal levels similar to maternal. |
| Breastfeeding | Naproxen and pseudoephedrine are excreted into breast milk in small amounts. Naproxen may cause gastrointestinal bleeding in infants. Pseudoephedrine may cause irritability and decreased milk production. Use with caution, preferably avoiding. |
■ FDA Black Box Warning
Cardiovascular thrombotic events: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use and in patients with cardiovascular disease or risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
| Common Effects | Insomnia |
| Serious Effects |
Hypersensitivity to naproxen, pseudoephedrine, or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive or history of peptic ulcer disease, gastrointestinal bleeding, or perforationSevere hypertension or coronary artery diseaseSevere hepatic impairment (Child-Pugh C)Severe renal impairment (CrCl <30 mL/min)Concomitant use of MAO inhibitors or within 14 daysThird trimester of pregnancyHistory of cerebrovascular accident or hemorrhagic stroke
| Precautions | Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; renal toxicity; anaphylactic reactions; skin reactions (e.g., Stevens-Johnson syndrome); exacerbation of asthma; caution in elderly, hepatic or renal impairment; fluid retention; use with alcohol or other NSAIDs increases risk of GI bleeding; avoid concomitant use with other sympathomimetics. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - cautious use |
| Teratogenic Risk | First trimester: NSAID use associated with increased risk of miscarriage and cardiac defects (limited data). Second trimester: Generally considered low risk; NSAIDs may cause oligohydramnios. Third trimester: Avoid due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal impairment; pseudoephedrine may cause fetal tachycardia and potential uteroplacental vasoconstriction. |
| Fetal Monitoring | Monitor fetal heart rate, amniotic fluid volume (ultrasound), and uterine contractions during third-trimester exposure. Assess maternal blood pressure for pseudoephedrine effects. In neonates, observe for signs of NSAID toxicity (e.g., gastrointestinal bleeding, renal impairment). |
| Fertility Effects | Naproxen may impair fertility by inhibiting ovulation in women (reversible on discontinuation) and may affect spermatogenesis in animal studies. Pseudoephedrine has no known significant fertility effects. |
| Food/Dietary | Avoid high-tyramine foods (e.g., aged cheeses, cured meats, soy sauce, beer, wine, yeast extracts) as pseudoephedrine may interact with MAOIs (though combination is contraindicated with MAOIs). Limit caffeine intake as pseudoephedrine may increase stimulant effects. Naproxen absorption is delayed if taken with food; take on an empty stomach for faster onset or with food if GI upset occurs. |
| Clinical Pearls | Naproxen sodium (NSAID) and pseudoephedrine HCl (decongestant) combination is used for sinus/nasal congestion with pain. Avoid in patients with hypertension (HTN), cardiovascular disease, renal impairment, or history of GI bleeding. Pseudoephedrine may cause insomnia, anxiety, or palpitations; naproxen increases bleeding risk and may cause renal toxicity. Advise caution in elderly and those on antihypertensives, anticoagulants, or other NSAIDs. Use shortest duration. |
| Patient Advice | Do not exceed recommended dose or duration (typically 3-5 days). · Avoid alcohol and other NSAIDs (e.g., ibuprofen, aspirin) to reduce GI bleeding risk. · Report signs of bleeding (e.g., black/tarry stools, vomit with blood) or cardiovascular symptoms (e.g., chest pain, shortness of breath). · Pseudoephedrine may cause dizziness or insomnia; avoid driving if affected. · Do not use if you have high blood pressure, heart disease, glaucoma, or thyroid problems unless directed by a doctor. |